Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Sources: biopharmadive.com · endpoints.news · qz.com

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at biopharmadive.com →

Report a problem with this story

More in Health & Medicine

More from Thursday 8 October →